Empagliflozin in Hypertrophic Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 250 participants.
Also called NCT05182658
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 250 participants
- Registry
-
NCT05182658
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05182658. Randomized; triple masking; primary purpose treatment. Start 2022-06-01 (actual); primary completion 2026-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin in Hypertrophic Cardiomyopathy
- Acronym
- EMPA-REPAIR
- Condition
- Hypertrophic Cardiomyopathy
- Condition
- Heart Failure
- Intervention (Drug)
- Empagliflozin 10 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- National Institute of Cardiology, Warsaw, Poland
- Collaborator
- Medical University of Bialystok
- Collaborator
- University of Eastern Finland
- Collaborator
- Amsterdam UMC, location VUmc
Record details
- Record id
cardio:ct-nct05182658- Content hash
e707e1705d96e986a7dcb6fe5512926315cbc8c3c712bd638978cbe8aeb9c440